Haemonetics Corporation
HAE
$53.12
-$0.62-1.15%
NYSE
| 06/28/2025 | 03/29/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -2.78% | -5.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.78% | -5.15% | |||
| Cost of Revenue | -1.45% | -11.57% | |||
| Gross Profit | -3.67% | -0.38% | |||
| SG&A Expenses | -14.34% | 10.36% | |||
| Depreciation & Amortization | 0.85% | -7.64% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.31% | -3.08% | |||
| Operating Income | 14.20% | -13.99% | |||
| Income Before Tax | -36.15% | 41.71% | |||
| Income Tax Expenses | -12.68% | 2.68% | |||
| Earnings from Continuing Operations | -41.31% | 54.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.31% | 54.64% | |||
| EBIT | 14.20% | -13.99% | |||
| EBITDA | 19.55% | -17.62% | |||
| EPS Basic | -39.99% | 58.07% | |||
| Normalized Basic EPS | 31.67% | -21.68% | |||
| EPS Diluted | -40.61% | 59.27% | |||
| Normalized Diluted EPS | 31.78% | -21.59% | |||
| Average Basic Shares Outstanding | -2.20% | -2.17% | |||
| Average Diluted Shares Outstanding | -2.27% | -2.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||